AI Article Synopsis

Article Abstract

Objective: To identify the genetic defect of coagulation factor VII in a Chinese family with hereditary FVII deficiency.

Methods: Peripheral blood samples were collected from the proband of hereditary FVII deficiency, female, aged 15, 4 members of her family, and 100 healthy persons. Genomic DNA was isolated. All the exons and exon-intron boundaries of FVII gene were amplified by PCR, then the PCR products were sequenced by direct sequencing. Restrictive endonuclease analysis was performed in all of the family members and the 100 healthy donors to exclude gene polymorphism. Biostructural analysis of the mutated FVII was completed by molecular modeling.

Results: Double heterozygous mutations in the proband were identified: A-->G mutation at position 10833 and C-->A mutation at position 9643, resulting in Met306Val and Thr181Asn substitution respectively. Heterozygosity for Met306Val was confirmed in the proband's mother and her elder sister; heterozygosity for Thr181Asn was confirmed in the proband's father. It was found by computer simulated molecular model that the Met306Val replacement, which was located on the surface of the FVII molecule, might cause steric hindrance and change the configuration and function of FVII protein.

Conclusion: Double heterozygous mutations for Met306Val and Thr181Asn in FVII gene have been found in a proband with hereditary FVII deficiency. The Met306Val substitution in FVII gene is a novel mutation in hereditary FVII deficiency. The heterozygous mutation of FVII gene may change the configuration of FVII protein and result in FVII dysfunction.

Download full-text PDF

Source

Publication Analysis

Top Keywords

hereditary fvii
16
fvii gene
16
fvii
13
double heterozygous
12
heterozygous mutations
12
met306val thr181asn
12
fvii deficiency
12
mutations met306val
8
coagulation factor
8
factor vii
8

Similar Publications

Background: Congenital factor VII (FVII) deficiency is a genetic disorder characterized by decreased FVII activity, which sometimes leads to fatal bleeding. Numerous variants have been found in FVII deficiency, but mutations vary among patients. Each mutation deserves further exploration for each patient at risk of bleeding.

View Article and Find Full Text PDF

Hereditary coagulation factor VII deficiency caused by novel compound heterozygous mutations c.572-1G>A and c.1037A>C in a Chinese pedigree.

Gene

November 2024

Department of Immunology, Special Key Laboratory of Gene Detection and Therapy of Guizhou Province, Zunyi Medical University, Guizhou, China. Electronic address:

Hereditary coagulation factor VII (FVII) deficiency is a rare autosomal recessive bleeding disorder. The aims of this study were to identify and verify the pathogenic mutation sites in a family with hereditary coagulation FVII deficiency, and preliminarily explore the underlying mechanisms. We identified a novel combination of compound heterozygous mutations, c.

View Article and Find Full Text PDF

Hereditary factor VII (FVII) deficiency is an uncommon autosomal recessive disorder associated with mutations in the F7 gene, and laboratory investigations usually reveal isolated prolongation in prothrombin time (PT)/international normalized ratio (INR). Venom-induced consumptive coagulopathy (VICC) is distinguished by the activation of the coagulation pathway, which is triggered by procoagulant toxins in snake venom. Diagnosing snakebites in patients with hereditary FVII deficiency presents a challenge because prolonged time PT/INR is considered the most valuable diagnostic method for VICC.

View Article and Find Full Text PDF
Article Synopsis
  • - The STASEY study assessed the safety and tolerability of emicizumab prophylaxis in hemophilia A patients with FVIII inhibitors, focusing on surgeries and postoperative bleeds in participants aged 12 and older.
  • - A total of 46 participants had surgeries during the study; out of these, 37 had minor surgeries and 13 had major surgeries, with varying rates of treated postoperative bleeds associated with the surgeries and additional medications.
  • - Overall, the study found that major surgeries were feasible for patients on emicizumab, with 59.1% of major surgeries resulting in postoperative bleeds, but no serious thrombotic complications were linked to the treatments used.
View Article and Find Full Text PDF

Introduction: Factor X deficiency is a rare inherited bleeding disorder. To date, 181 variants are reported in the recently updated F10-gene variant database.

Aim: This study aimed to describe new F10 variants.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!